03309 C-MER MEDICAL
- 2.010
- +0.100+5.24%
C-MER MEDICAL News
Shares of Xima Medical (03309) fell 39.00%, now trading at HKD 1.820, hitting a 52-week low.
As of 11:46, Xima Medical (03309) has dropped 39.00% compared to the previous closing price, currently at 1.820 yuan, hitting a new 52-week low; the volume of trade is 0.538 million shares, with a turnover of 0.9845 million Hong Kong dollars.
Healthcare company Sima Medical (03309) plans to use up to 0.1 billion Hong Kong dollars of cash to repurchase shares in the market.
Himax Medical (03309) has announced that the board of directors has been closely monitoring the recent stock price of the company and making decisions based on the 202...
Express News | C-Mer Eye Care - Apply up to HK$100 Mln of Its Cash to Repurchase Shares
It's Down 27% But C-MER Medical Holdings Limited (HKG:3309) Could Be Riskier Than It Looks
Returns On Capital At C-MER Medical Holdings (HKG:3309) Paint A Concerning Picture
Haemonetics (03309) spent about 1.8869 million Hong Kong dollars to repurchase 0.82 million shares on August 30th.
Sigma Medical (03309) announced that on August 30, 2024, it will spend approximately 1.8869 million Hong Kong dollars to repurchase 0.82 million...
C-MER Eye Care Posts 3% Rise in H1 Profit; Revenue Slips 3%
Hima Medical announced its interim results, with shareholders' share of profits for the period of 30.763 million Hong Kong dollars, a year-on-year increase of 3.4%.
Hima Medical (03309) announced its mid-term performance for 2024, with revenue of 0.9225 billion Hong Kong dollars, a year-on-year decrease of 2.9%; gross profit of approximately 0.289 billion Hong Kong dollars, a year-on-year decrease of 3.7%; the company's equity holders' share of profit for the period was 30.763 million Hong Kong dollars, a year-on-year increase of 3.4%; earnings per share were 2.48 Hong Kong cents. The announcement stated that the slight decrease in revenue was due to the decrease in income from ophthalmic services in Hong Kong and mainland China due to negative market sentiment and economic uncertainties, and the increase in income from the dental services under the "Shenzhen Aikangjian" brand due to the trend of Hong Kong residents traveling to Shenzhen for consumption.
The mid-year surplus of Hima Medical (03309) increased by 3.38% year-on-year with no interim dividend.
Golden Financial News | Xima Medical (03309) announced that as of June 30, 2024, the company's equity holders' share of profit was 30.763 million yuan (Hong Kong dollars, the same below), a year-on-year increase of 3.38%, with basic earnings per share of 2.48 cents. No interim dividend will be distributed. During the period, the Group's revenue was 0.923 billion yuan, a decrease of 2.92% year-on-year. During the period, the Group's medical business revenue from Hong Kong operations decreased by 9.0% to 0.427 billion yuan, mainly including a 6% decrease in revenue from the Hong Kong ophthalmology business (including providing ophthalmic services and selling vision aids) in the first half of 2024.
Hima Medical (03309.HK) total revenue in the first half of the year was 0.92 billion Hong Kong dollars, a slight decrease of 2.9% year-on-year.
On August 29th, Gelonghui announced that in the first half of 2024, the company's total revenue was HK$922.5 million, a slight decrease of 2.9% compared to the same period in 2023. This is due to (i) a 0.9% decrease in core medical service revenue (including ophthalmology services, dental and other medical services, and sales of vision aids) to HK$922.5 million from HK$930.8 million in the same period last year; and (ii) a decrease in revenue from the sale of COVID-19 related medical supplies from HK$19.4 million in the same period last year to HK$20.
Express News | C-Mer Eye Care - Not Recommend Payment of an Interim Dividend
Express News | C-Mer Eye Care Holdings H1 Gross Profit HKD 289.1 Million
C-MER MEDICAL: INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024
Hema medical (03309.HK) plans to hold a board of directors meeting on August 29th to approve the mid-term performance
Hima Medical (03309.HK) announced on August 14 that a board of directors meeting will be held on Thursday, August 29, 2024 to handle the following matters: 1. Approval of the interim performance announcement for the company and its subsidiaries six months ending on June 30, 2024; 2. Consideration of proposing the payment of interim dividends (if any); and 3. Dealing with any other matters.
C-MER MEDICAL: NOTICE OF BOARD MEETING
Hima Medical received an increase in shareholding of 0.348 million shares of the company's stock from the CEO and executive director, Lin Shunchao.
Sihuan Pharmaceutical Holdings Group Ltd. (03309) announced that the board of directors of the company was informed by the company's chairman, CEO and executive director, Lin Shunchao, that he had purchased a total of 0.348 million shares of the company's stock in the market on July 22, 2024, at a total cost of HKD 0.9203 million, equivalent to an average price of about HKD 2.64 per share and accounting for approximately 0.028% of the company's issued share capital.
Hima Medical (03309.HK) received Chairman, CEO and Executive Director Lin Shunchao's shareholding of 0.358 million shares.
Hithink RoyalFlush announced on July 19th that the Board of Directors was informed by the Chairman, CEO and Executive Director, Lin Shunchao, that he had purchased a total of 0.358 million shares of the company on the market since July 18, 2024, at a total cost of HKD 949,940, which is an average price of approximately HKD 2.65 per share and accounts for approximately 0.029% of the company's issued share capital.
Hima Medical received an increase in shareholding of 0.792 million shares by the Executive Director and CEO Lin Shunchao.
Hima Medical (03309) announced that the Board of Directors (Board of Directors) of the company has been informed by Dr. Lin Shunchao, the chairman, CEO and executive director of the company, that he has purchased a total of 0.792 million shares of the company's stock on the market since July 15, 2024, at a total cost of HKD 2.077 million, with an average price of about HKD 2.62 per share (for the purchase from July 15 to July 17), accounting for approximately 0.063% of the company's issued share capital. Prior to the purchase from July 15 to July 17, Dr. Lin, together with Hima Group Limited (the company's controlling shareholder)
Express News | C-Mer Eye Care - CEO Purchased 792,000 Shares of Co for HK$2.1 Mln
C-MER Medical Renews Lease for Shenzhen Eye Hospital Property
Analysis
Price Target
No Data
